aggregation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
== Structure == The notochord is a long, rod-like midline structure that develops dorsal to the gut tube and ventral to the neural tube. The notochord is composed primarily of a glycoproteins core that is encased in a sheath of collagen fibers. This is wound into two opposing helices. The glycoproteins are stored in vacuolated, turgid cells, which are covered with caveolae on their cell surface. The angle between these fibers determines whether increased pressure in the core will result in shortening and thickening versus lengthening and thinning. Alternating contraction of muscle fibers attached to each side of the notochord result in a side-to-side motion resembling stern sculling, which allows locomotion. The stiffened notochord prevents movement through telescoping motion such as that of an earthworm.
=== DNA === Forensic DNA analysis was first used in 1984. It was developed by Sir Alec Jeffreys, who realized that variation in the genetic sequence could be used to identify individuals and to tell individuals apart from one another. The first application of DNA profiles was used by Jeffreys in a double murder mystery in the small English town of Narborough, Leicestershire, in 1985. A 15-year-old school girl by the name of Lynda Mann was raped and murdered in Carlton Hayes psychiatric hospital. The police did not find a suspect but were able to obtain a semen sample. In 1986, Dawn Ashworth, 15 years old, was also raped and strangled in the nearby village of Enderby. Forensic evidence showed that both killers had the same blood type. Richard Buckland became the suspect because he worked at Carlton Hayes psychiatric hospital, had been spotted near Dawn Ashworth's murder scene and knew unreleased details about the body. He later confessed to Dawn's murder but not Lynda's. Jefferys was brought into the case to analyze the semen samples. He concluded that there was no match between the samples and Buckland, who became the first person to be exonerated using DNA. Jefferys confirmed that the DNA profiles were identical for the two murder semen samples. To find the perpetrator, DNA samples from the entire male population, more than 4,000 aged from 17 to 34, of the town were collected. They all were compared to semen samples from the crime. A friend of Colin Pitchfork was heard saying that he had given his sample to the police claiming to be Colin.
==== Dark Messiah of Might and Magic (2006) and cancelled projects ==== Antonov joined French developer Arkane Studios. He was a level designer for their 2006 action role-playing game (RPG) Dark Messiah of Might And Magic, helping his team replicate Valve's process of making levels for Half-Life 2. Around 2007 and 2008, Arkane began developing an officially licensed Half-Life sequel, centered around the alien zombies that infest the ghost town of Ravenholm in Half-Life 2. Antonov continued helping Arkane replicate Valve's design process. The project was soon scrapped, because they did not develop it in the time that Valve wanted, and Valve was having trouble deciding where Half-Life as a series should go while making its episodic entries. Arkane's then-president Raphaël Colantonio has said that Antonov's work on the project "was pivotal to what would become Arkane later", as "he trained us in all of [Valve's] practices in terms of art, in terms of how to think of a level, [and] how to think of architecture". Antonov was a level designer for the studio's next project, an FPS titled The Crossing, for which he created a sci-fi version of Paris. In 2009, this project was also cancelled, as Arkane was unable to secure financing for it, as well as a publisher that would let them retain the game's intellectual property rights in the future. However, elements of The Crossing later came to fruition in Arkane's 2021 FPS Deathloop.
== Incubation length == Incubation times vary based upon the microbe that requires culturing. Traditional culturing techniques, for example, require less than 24 hours culture time for Escherichia coli but 6–8 weeks for successful culturing of Mycobacterium tuberculosis before definitive results are expressed. A benefit of non-culture tests is that physicians and microbiologists are not handicapped by waiting periods. Incubation follows a growth curve variable for every microorganism. Cultures follow a lag, log, stationary, and finally death phase. The lag phase is not well known in microbiology, but it is speculated that this phase consists of the microorganism adjusting to its environment by synthesizing proteins specific for the surrounding habitat. The log phase is the period where a culture experiences logarithmic growth until nutrients become scarce. The stationary phase is when culture concentration is the highest and cells stop reproducing. When nutrients in the environment are depleting, organisms enter the death phase where toxic metabolites become abundant and nutrients are depleted to the point where cell death exceeds reproduction.
== Awards == 1973 - 25th Annual Institute Lecturer, American Institute of Chemical Engineers 1975 - Food, Pharmaceutical and Bioengineering Division Award, American Institute of Chemical Engineers 1976 - William H. Walker Award, American Institute of Chemical Engineers 1978 - George Westinghouse Award, American Society for Engineering Education 1981 - Member, National Academy of Engineering 1983 - Fellow, American Institute of Chemical Engineers 1988 - Ninth Centennial Lecturer in Chemical Engineering, University of Bologna 1990 - Award for Excellence in Drying Research, International Drying Symposium 1990 - Mac Pruitt Award, Council for Chemical Research 1990 - Warren K. Lewis Award, American Institute of Chemical Engineers 1992 - Clarence G. Gerhold Award, Separations Division of AIChE 1993 - Fellow, American Association for the Advancement of Science 1993 - Centennial Medallion, American Society for Engineering Education 1997 - Award in Separations Science and Technology, American Chemical Society 1998 - Outstanding Alumnus, Yale Science and Engineering Association, Yale University 1998 - The Electrochemical Society Lecture, The Electrochemical Society 2009 - 100 Chemical Engineers of the Modern Era, Amer. Institute of Chemical Engineers 2018 - Clark Kerr Award, Academic Senate, University of California, Berkeley
Sources: en.wikipedia.org
==== Remoting ==== Component methods may be made available as web services with no additional coding and configuration. All that is required is for a method's access to be declared 'remote'. ColdFusion automatically generates a WSDL at the URL for the component in this manner: http://path/to/components/Component.cfc?wsdl. Aside from SOAP, the services are offered in Flash Remoting binary format. Methods which are declared remote may also be invoked via an HTTP GET or POST request. Consider the GET request as shown.
== History == Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL (Phenethylamines I Have Known and Loved) under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. 2C-T-36 was ultimately first synthesised and named by Geoffrey Varty and colleagues at Irish biopharmaceutical company Helus Pharma (formerly Cybin) in 2023.
Short-term side effects, as with all glucocorticoids, include high blood glucose levels (especially in patients with diabetes mellitus or on other medications that increase blood glucose, such as tacrolimus) and mineralocorticoid effects such as fluid retention. The mineralocorticoid effects of prednisone are minor, which is why it is not used in the management of adrenal insufficiency unless a more potent mineralocorticoid is administered concomitantly. It can also cause depression or depressive symptoms and anxiety in some individuals. Long-term side effects include Cushing's syndrome, steroid dementia syndrome, truncal weight gain, glaucoma and cataracts, diabetes mellitus type 2, and depression upon dose reduction or cessation. Long-term steroids can also increase the risk of osteoporosis, but research has found that few of these people were taking medications to protect bones. Prednisone also results in leukocytosis.
=== N-Substitution === The N-functionalization of the isatin core can be readily obtained by the deprotonation of the amino moiety, forming the corresponding sodium or potassium salt, and subsequent addition of an electrophile (e.g. alkyl or acyl halides).
Sources: en.wikipedia.org
== Development == The earliest documented signs of development began on June 18, 2007, on the modding site Mod DB. A post by "RYell", the lead developer for the game, showcased weapon models and stated that internal testing would occur during July of that year. Two months later on August 29th, a new post would showcase the Sharps Rifle 1874 and the Henry Rifle. Concept art for one of the teams, the Desperado, and in-game screenshots of the map FoF_Tramonto were shown. A month later on September 27th, an update was posted which highlighted new contributors, such as Sonic Valley Production who provided sound effects and Steve Mazzaro who composed the main theme and end round theme. The development showcased new weapons and gave a look into gameplay. Closed Beta had begun. After a few months, on December 19th, the game had been announced to release in open beta on the 21st. With main features being promised including:
N-Acetylglutamate synthase (NAGS) is an enzyme in humans is encoded by the gene NAGS. It catalyses the production of N-acetylglutamate (NAG) from glutamate and acetyl-CoA. Put simply NAGS catalyzes the following reaction:
2,5-DKPs are synthesized by a variety of organisms including humans. In general, they arise by the action of a tRNA-dependent cyclodipeptide synthases, a type of enzyme responsible for creating a cyclic amide linkage between two peptides. The enzymes cyclodipeptide oxidase and S-adenosyl-methionine-dependent O/N methyltransferases act in tandem to chemically modify cyclic dipeptides. 2,5-Diketopiperazines are typically prepared by one of three methods: amide bond formation, N-alkylation and C-acylation.
MacKinnon, Charlotte M.; Carter, Philip E.; Smyth, S. Jane; Dunbar, Bryan; Fothergill, John E. (1987). "Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence". European Journal of Biochemistry. 169 (3): 547–553. doi:10.1111/j.1432-1033.1987.tb13644.x. PMID 3500856. Snoke, JE; Yanari, S; Bloch, K (1953). "Synthesis of glutathione from gamma-glutamylcysteine". The Journal of Biological Chemistry. 201 (2): 573–586. doi:10.1016/S0021-9258(18)66212-X. PMID 13061393. Mandeles, S; Block, K (1955). "Enzymatic synthesis of gamma-glutamylcysteine". The Journal of Biological Chemistry. 214 (2): 639–646. doi:10.1016/S0021-9258(18)70912-5. PMID 14381401.
In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tuznue, intended for the treatment of breast and gastric cancer. The applicant for this medicinal product is Prestige Biopharma Belgium BVBA. Tuznue is a biosimilar medicinal product. Tuznue was authorized for medical use in the European Union in September 2024. Adheroza was approved for medical use in Canada in August 2024. In April 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dazublys, intended for the treatment of breast and gastric cancer. The applicant for this medicinal product is CuraTeQ Biologics s.r.o. Dazublys is a biosimilar medicinal product that is highly similar to the reference product Herceptin (trastuzumab), which was authorized in the EU in August 2000. Dazublys was authorized for medical use in the EU in June 2025.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.